Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Inovio Pharmaceuticals (NASDAQ:INO) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Positive Sentiment: INO-3107’s FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed.
• Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity.
• Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results.
• Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July’s $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises.
• Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases.

Inovio Pharmaceuticals Trading Up 16.4%

Shares of Inovio Pharmaceuticals stock traded up $0.13 during trading hours on Thursday, hitting $0.90. 5,916,458 shares of the company were exchanged, compared to its average volume of 2,315,768. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98. The stock has a market capitalization of $73.71 million, a price-to-earnings ratio of -0.62 and a beta of 1.52. The business has a 50-day moving average of $1.03 and a 200-day moving average of $1.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Inovio Pharmaceuticals in the third quarter worth $33,000. Raymond James Financial Inc. boosted its stake in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Inovio Pharmaceuticals in the 3rd quarter valued at about $41,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 18,160 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: Inovio reported a second-quarter loss of $0.07 per share, substantially narrower than analysts’ expected loss of $0.22 per share. Inovio quarterly earnings report
• Positive Sentiment: The FDA review of the biologics license application for INO-3107, Inovio’s treatment for recurrent respiratory papillomatosis, is advancing toward an October 30, 2026 PDUFA decision date. The company is also preparing for a potential launch. INOVIO second-quarter results and business highlights
• Positive Sentiment: Management said its cash, cash equivalents, and short-term investments are expected to fund operations into late first quarter 2027, potentially carrying the company through an INO-3107 launch if approved. This reduces near-term financing concerns. Inovio Q2 2026 earnings call highlights
• Positive Sentiment: Inovio’s Chinese partner, ApolloBio, reported positive topline Phase 3 results for VGX-3100 in cervical dysplasia, providing additional clinical and partnership momentum. INOVIO financial results and business highlights
• Neutral Sentiment: The company also presented encouraging data from its next-generation DMAb and DPROT platforms, but these earlier-stage programs are less immediate potential catalysts than the INO-3107 regulatory decision. Inovio Q2 2026 earnings call transcript
• Negative Sentiment: Inovio remains unprofitable, and the stock’s outlook is highly dependent on FDA approval and successful commercialization of INO-3107. Failure or delay could renew cash-burn and financing concerns.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INO. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and set a $3.00 target price on the stock in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st. Finally, HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.17.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.